Growth Metrics

Kiniksa Pharmaceuticals International (KNSA) Depreciation & Amortization (CF) (2021 - 2025)

Historic Depreciation & Amortization (CF) for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $384000.0.

  • Kiniksa Pharmaceuticals International's Depreciation & Amortization (CF) fell 375.94% to $384000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 1896.46%. This contributed to the annual value of $1.7 million for FY2024, which is 2759.5% down from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Depreciation & Amortization (CF) of $384000.0 as of Q3 2025, which was down 375.94% from $358000.0 recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Depreciation & Amortization (CF) ranged from a high of $717000.0 in Q2 2021 and a low of $312000.0 during Q1 2021
  • Over the past 5 years, Kiniksa Pharmaceuticals International's median Depreciation & Amortization (CF) value was $540000.0 (recorded in 2023), while the average stood at $520000.0.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Depreciation & Amortization (CF) surged by 11025.64% in 2022, and later crashed by 3383.08% in 2024.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Depreciation & Amortization (CF) (Quarter) stood at $668000.0 in 2021, then fell by 9.88% to $602000.0 in 2022, then fell by 10.3% to $540000.0 in 2023, then dropped by 25.93% to $400000.0 in 2024, then dropped by 4.0% to $384000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $384000.0 in Q3 2025, compared to $358000.0 in Q2 2025 and $345000.0 in Q1 2025.